INLEXZO (gemcitabine intravesical system, formerly TAR-200)
FDA approved September 9, 2025 for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ; reimbursed in the US.
What it is
A drug-releasing device placed in the bladder that delivers gemcitabine over an extended period. It is aimed at patients with BCG-unresponsive bladder cancer that is not muscle-invasive.
Why it matters to the stock. A new urology franchise with few competing options for BCG-unresponsive disease. Early sales show whether bladder drug-release systems can become a durable product line.
News
No stories tagged to this project yet.